Loading…
← CockpitCompetitor Analysis › NAUT Nautilus Biotechnolgy, Inc.Open in the cockpit ↗

Nautilus Biotechnolgy, Inc.NAUTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 99
Mkt cap
$310M
US dollars, full cap
Free float
58%
of shares outstanding
$/day
$19.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-97.4 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$2.43
1D+3.0%
1W+0.4%
1M-4.7%
3M+169.3%
6M+2.1%
YTD+24.6%
1Y+27.9%
ATR %13.2%
Beta1.42
52w lowhigh43.6% off high

What Nautilus Biotechnolgy does

Employees: 130

Nautilus Biotechnolgy at a glance

Size Nautilus Biotechnolgy (NAUT) is a United States Health Care company (Biotechnology) with a market value of $310M, the 3054th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.43 on 18 Nov 2026.

Performance Over six months the shares gained 2.1%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.

Growth The operating margin is -15,105.7% (peer median -115.0%).

Valuation It trades at 588.9× enterprise value to sales against a peer median of 5.3× (4th most expensive of 15).

Capital Return on invested capital runs 97.4 points below its cost of capital (8.2% WACC).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026NAUT 96Peer median 69
Six months, rebased to 100: Nautilus Biotechnolgy against the median of its 20 peers (local-currency closes).

Nautilus Biotechnolgy financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$424,000$0$0$0$0
Revenue growth—————
Gross profit-$5.27M-$6.46M-$6.35M-$5.71M-$3.42M
EBITDA-$58.4M-$60.4M-$75.1M-$70.4M-$60.2M
Net income-$58.6M-$59.0M-$70.8M-$63.7M-$57.9M
Free cash flow-$55.1M-$52.0M-$61.3M-$54.2M-$48.1M
Capital expenditure$2.65M$1.28M$2.12M$2.44M$2.32M
Total debt$26.7M$30.0M$30.5M$34.6M$30.3M

Quarterly statements and history in the cockpit →

Nautilus Biotechnolgy competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%4894PROKXFOR1873GLSIGALT76306945CCCC2105LRMR358570LYEL086900CRMDCTNM476060NAUT6-month return →1-month return →
Up and to the right = strong over both horizons. Nautilus Biotechnolgy is the large dot.

Nautilus Biotechnolgy competitors and peer comparison

How Nautilus Biotechnolgy compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nautilus Biotechnolgy against its 20 peers (data as of 18 Nov 2026)
MeasureNAUTPeer medianRank in peer set
1-month return-4.7%-5.7%10th highest of 20
6-month return+2.1%-31.0%2nd highest of 20
Distance from 52-week high-43.6%-54.6%5th highest of 20
Operating margin-15,105.7%-115.0%3rd lowest of 15
EV / Sales588.9×5.3×4th most expensive of 15
ROIC minus cost of capital-97.4 pp-22.1 pp4th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are Nautilus Biotechnolgy's closest peers?
The cockpit's peer set: Cuorips (4894.T), ProKidney (PROK), X4 Pharmaceuticals (XFOR), Viva Biotech (1873.HK), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), IMPACT Therapeutics (7630.HK), AP Biosciences (6945.TWO).
Is Nautilus Biotechnolgy expensive compared with its peers?
On ev / sales it trades at 588.9× against a peer median of 5.3×, 4th most expensive of 15 in its peer set.
How has Nautilus Biotechnolgy stock performed?
Over six months to 18 Nov 2026 the shares returned +2.1% against -31.0% for the median peer; over one year +27.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.